Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Idiopathic cardiomyopathy].

Haruo Mitani1, Shin-ichi Momomura

  • 1Cardiovascular Center Toranomon Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined GLIM-defined malnutrition and sarcopenia and the risk of 2-year mortality in adults with heart failure: A FRAGILE-HF study post hoc analysis.

JPEN. Journal of parenteral and enteral nutrition·2026
Same author

Prognostic impact of residual symptoms under low and normal physical performance in older patients hospitalized for worsening heart failure.

Archives of gerontology and geriatrics·2026
Same author

Prognostic value of GLIM criteria with and without inflammation assessment in older patients with heart failure: FRAGILE-HF cohort.

Clinical nutrition ESPEN·2026
Same author

Association of Muscle-specific Strength With Impaired Physical Function and Prognosis in Heart Failure: A Comparison With Muscle Strength.

Journal of the American Medical Directors Association·2026
Same author

Comparative prognostic value of three frailty-assessment tools in older patients with heart failure: post hoc analysis of the FRAGILE-HF cohort.

Age and ageing·2026
Same author

Fat Mass and Cause-Specific Death in Older Patients with Heart Failure.

The Canadian journal of cardiology·2025
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Cardiomyopathies are myocardial diseases causing cardiac dysfunction. While treatments exist for heart failure, sudden cardiac death remains a risk, but implantable cardioverter-defibrillators offer protection.

Area of Science:

  • Cardiology
  • Cardiac Electrophysiology

Context:

  • Cardiomyopathies encompass a group of myocardial diseases characterized by cardiac dysfunction.
  • Key types include dilated, hypertrophic, and restrictive cardiomyopathies, each with distinct pathophysiological features.
  • Sudden cardiac death from arrhythmia is a primary concern in cardiomyopathy patients, alongside heart failure.

Purpose:

  • To review the classification and clinical characteristics of cardiomyopathies.
  • To highlight the significant risk of sudden death in cardiomyopathy patients.
  • To discuss current therapeutic strategies and the role of implantable cardioverter-defibrillators.

Summary:

  • Cardiomyopathies are myocardial diseases leading to impaired heart function, classified into dilated, hypertrophic, and restrictive types.

Related Experiment Videos

  • While ACE inhibitors and beta-blockers manage heart failure, they do not fully mitigate the high risk of sudden death.
  • Clinical trials indicate that implantable cardioverter-defibrillators (ICDs) are effective in preventing sudden cardiac death in this patient population.

    • Impact:

    • Provides a concise overview of cardiomyopathy types and their associated risks.
    • Emphasizes the critical role of implantable cardioverter-defibrillators in reducing mortality from sudden cardiac death.
    • Informs clinical decision-making regarding advanced therapies for cardiomyopathy management.